Subcutaneous Immunoglobulin in Oncology Clinical Practice

Area of Science:

• Oncology
• Immunology
• Healthcare Management

Background:

• Patients with malignancy-related immunodeficiency often require gammaglobulin replacement therapy.
• Intravenous (IV) gammaglobulin is the traditional formulation for this therapy.
• Limitations of IV administration include the need for clinical settings and potential patient burden.

Purpose of the Study:

• To evaluate the feasibility and impact of transitioning cancer patients to subcutaneous immunoglobulin (SCIG) infusions.
• To assess the benefits of home-based, self-administered SCIG for patients and healthcare institutions.
• To highlight the role of advanced practice nurses (APNs) in implementing innovative supportive care.

Main Methods:

• A pilot program was initiated at a Canadian cancer center.
• The program focused on transitioning patients from IV gammaglobulin to self-administered SCIG at home.
• The implementation was led by an advanced practice nurse (APN).

Main Results:

• The transition to SCIG resulted in cost savings for the institution.
• Patients experienced benefits from home-based, self-administered infusions.
• The APN-led implementation demonstrated a successful shift in supportive care delivery.

Conclusions:

• Home-based SCIG is a viable and beneficial alternative to IV gammaglobulin for cancer patients with immunodeficiency.
• APN leadership is crucial for implementing innovative, patient-centered supportive care models.
• This approach offers a novel strategy for optimizing supportive care in oncology settings.